Nitracrine N-oxides: Effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity

Anti-Cancer Drug Design

Volumn 14, Issue 6, 1999, Pages 487-497

  Lee, Ho H ^a   Wilson, William R ^a   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Hypoxic selectivity; N oxide; Nitracrine; Nitroacridine; Tertiary amine

Indexed keywords

1 NITRO 9 (3 MORPHOLINOPROPYL)AMINOACRIDINE; 1 NITRO 9 (3 MORPHOLINOPROPYL)AMINOACRIDINE N3 OXIDE; 1 NITRO 9 N [3 (1 PIPERIDINO)PROPYL]AMINOACRIDINE OXIDE; 2(2 AMINOETHYL)PYRIDINE OXIDE; 3 (1 PIPERIDINO)PROPANAMINE; 3 DIMETHYLAMINO 3 METHYLBUTYLAMINE; 9 [[2 (2 PYRIDYL)ETHYL]AMINO] 1 NITROACRIDINE PYRIDINE OXIDE; 9 [[2 (N,N DIMETHYLAMINO)ETHYL]AMINO] 1 NITROACRIDINE N2 OXIDE; 9 [[3 N,N DIISOPROPYLAMINO]PROPYLAMINO] 1 NITROACRIDINE N3 OXIDE; 9 [[3 N,N DIMETHYLAMINO 3 DIMETHYL]PROPYLAMINO] 1 NITROACRIDINE N3 OXIDE; DNA; N,N DIISOPROPYLAMINO 1,3 PROPANEDIAMINE; NITRACRINE DERIVATIVE; OXIDE; TERTIARY AMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CHO CELL; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA ALKYLATION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG STRUCTURE; EXCISION REPAIR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REDUCTION; STEREOSPECIFICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL SURVIVAL; CLONE CELLS; DRUG DESIGN; HUMANS; INDICATORS AND REAGENTS; KINETICS; MALE; MICE; MICE, INBRED C3H; NITRACRINE; OXIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

ANIMALIA; CRICETINAE; CRICETULUS GRISEUS;

EID: 0033511998     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Back T.G., Barton D.H.R. (1977) Chemistry of hindered amines. Synthesis and properties of di-t-butylamine and related compounds. Journal of the Chemical Society Perkin Transactions I, 924.
2. Bickel M.H. (1969) The pharmacology and biochemistry of N-oxides. Pharmacology Reviews, 21, 325.
3. Brown J.M., Siim B.G. (1996) Hypoxia specific cytotoxins in cancer therapy. Seminars in Radiation Oncology, 6, 22.
4. Chen T.R. (1977) In situ detection of Mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Experimental Cell Research, 104, 255.
5. Davis F.A., Stringer C.D. (1982) Chemistry of oxaziridines. 2. Improved synthesis of 2-sulfonyloxaziridines. Journal of Organic Chemistry, 47, 1775.
6. de Laat W.L., Jaspers N.J., Hoeijmakers J.H. (1999) Molecular mechanism of nucleotide excision repair. Genes and Development, 13, 768.
7. Denny W.A., Atwell G.J., Anderson R.F., Wilson W.R. (1990) Hypoxia-selective antitumor agents. 4. Relationships between structure, physicochemical properties, and hypoxia-selective cytotoxicity for nitracrine analogues with varying side chains: the 'imidoacridan' hypothesis. Journal of Medicinal Chemistry, 33, 1288.
8. Denny W.A., Wilson W.R., Tercel M., Van Zijl P., Pullen S.M. (1994) Benzylic mustard quaternary salts: a new class of hypoxia-selective cytotoxins capable of releasing diffusible cytotoxins on bioreduction. International Journal of Radiation Oncology, Biology and Physics, 29, 317.
9. Finlay G.J., Baguley B.C., Wilson W.R. (1984) A semi-automated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Analytical Biochemistry, 139, 272.
10. Guengerich F.P. (1991) Reactions and significance of cytochrome P450 enzymes. Journal of Biological Chemistry, 266, 10019.
11. Hay M.P., Wilson W.R., Moselen J.W., Palmer B.D., Denny W.A. (1994) Hypoxia-selective antitumour agents. 8. Bis-(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radio-sensitisers. Journal of Medicinal Chemistry, 37, 381.
12. Hoy C.A., Thompson L.H., Mooney C.L., Salazar E.P. (1985) Defective DNA cross-link removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents. Cancer Research, 45, 1737.
13. Konopa J., Koldej K., Pawlak J.W. (1976) Covalent binding of 1-nitro-9-(3′-dimethyl-n-propylamino)acridine, a new anti-tumor drug, to DNA of Ehrlich ascites tumor cells in vivo. Chemico-Biological Interactions, 13, 99.
14. Ledochowski A. (1966) Tumor inhibiting compounds. XXXIV. Syntheses of 9-N,N-dimethylhydrazino- and 9-(-dimethylaminoethylamino) derivatives of 1-,2-,3-, and 4-nitroacridine. Roczniki Chemii, 40, 1557; Chemical Abstracts, 1967, 67, 64226u.
15. Ledochowski A. (1966) Tumor inhibiting compounds. XXXIV. Syntheses of 9-N,N-dimethylhydrazino- and 9-(-dimethylaminoethylamino) derivatives of 1-,2-,3-, and 4-nitroacridine. Roczniki Chemii, 40, 1557; Chemical Abstracts, 1967, 67, 64226u.
16. Ledochowski A., Stefanska B. (1966) Research on tumour-inhibiting compounds. XXIX. Some N-9 derivatives of 1-, 2-, 3- and 4-nitro-9-aminoacridine. Annals of the Polish Chemical Society, 40, 301.
17. Lee H.H., Denny W.A. (1999) A large-scale synthesis of the bioreductive drug 1,4-bis[[2-(dimethylamino)ethyl]amino]-5,8-dihydroxyanthracene-9,10-dione bis-N-oxide (AQ4N) Journal of the Chemical Society Perkin Transactions I, 2755.
18. Lee H.H., Wilson W.R., Ferry D.M., van Zijl P., Pullen S.M., Denny W.A. (1996) Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity of nitracrine N-oxide. Journal of Medicinal Chemistry, 39, 2508.
19. McKeown S.R., Hejmadi M.V., McIntyre I.A., McAleer J.J.A., Paterson L.H. (1995) AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation. British Journal of Cancer, 72, 76.
20. Mikhona E.E., Yanina A.D., Rubtsov M.V. (1969) Properties and some transformations of 4-oxo-1,5-diazabicyclo[4.4.0]-decane and 5-oxo-1,4-diazabicyclo[4.4.0]decane. Khimia Geterotsiklia Soedin, 547; Chemical Abstracts, 1969, 71, 124366j.
21. Mikhona E.E., Yanina A.D., Rubtsov M.V. (1969) Properties and some transformations of 4-oxo-1,5-diazabicyclo[4.4.0]-decane and 5-oxo-1,4-diazabicyclo[4.4.0]decane. Khimia Geterotsiklia Soedin, 547; Chemical Abstracts, 1969, 71, 124366j.
22. Patterson L.H. (1993) Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Reviews, 12, 119.
23. 14C-(3′-dimethylamino-n-propoylamino) acridine, a new antitumor and DNA cross-linking agent, to macromolecules of subcellular fractions isolated from rat liver and HeLa cells. Biochemical Pharmacology, 28, 3391.
24. Rauth A.M., Melo T., Mistra V. (1998) Bioreductive therapies: an overview of drugs and their mechanisms of action. International Journal of Radiation Oncology, Biology and Physics, 42, 755.
25. Saviganac P., Dreux M., Ple' G. (1973) Phosphoramide amines I. Syntheses of diamino-ethanes and diaminopropanes. Journal of Organometallic Chemistty, 60, 103.
26. Siim B.G., Atwell G.J., Wilson W.R. (1994) Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. British Journal of Cancer, 70, 596.
27. Siim B.G., Lee H.H., Pullen S.M., van Zijl P.V., Denny W.A., Wilson W.R. (1999) Comparison of aromatic and aliphatic N-oxides of acridine DNA intercalators as bioreductive drugs: cytotoxicity, DNA binding, cellular uptake and metabolism. Biochemical Pharmacology, in press.
28. Sugiura M., Iwasaki K., Kato R. (1977) Reduced nicotinamide adenine dinucleotide-dependent reduction of tertiary amine N-oxide by liver microsomal cytochrome P-450. Biochemical Pharmacology, 26, 489.
29. Tercel M., Wilson W.R., Anderson R.F., Denny W.A. (1996) Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. Journal of Medicinal Chemistry, 39, 1084.
30. Thompson L.H., Rubin J.S., Cleaver J.E., Whitmore G.F., Brookman K. (1980) A screening method for isolating DNA repair-deficient mutants of CHO cells. Somatic Cell Genetics, 6, 391.
31. Thomson J.E., Rauth A.M. (1974) An in vitro assay to measure the viability of KHT tumor cells not previously exposed to culture conditions. Radiation Research, 58, 262.
32. Wilson W.R., Denny W.A., Pullen S.M., Thompson K.M., Li A.E., Patterson L.H., Lee H.H. (1996) Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. British Journal of Cancer, 74 (suppl. XXVII), 43.
33. Wilson W.R., Denny W.A., Stewart G.M., Fenn A., Probert J.C. (1986) Reductive metabolism and hypoxia-selective cytotoxicity of nitracrine. International Journal of Radiation Oncology, Biology and Physics, 12, 1235.
34. Wilson W.R., Denny W.A., Twigden S.J., Baguley B.C., Probert J.C. (1984) Selective toxicity of nitracrine to hypoxic mammalian cells. British Journal of Cancer, 49, 215.
35. Wilson W.R., van Zijl P., Denny W.A. (1992) Bis-bioreductive agents as hypoxia-selective cytotoxins: N-oxides of nitracrine. (1992) International Journal of Radiation Oncology, Biology and Physics, 22, 693.
36. Wilson W.R., Thompson L.H., Anderson R.F., Denny W.A. (1989) Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives. Journal of Medicinal Chemistry, 32, 31.